The Great Reawakening: Mycoplasma Pneumoniae

Like Epstein-Barr and Herpesviruses, is this pathogen also exacerbated by SARS-CoV-2 and its Spike Protein?

Pathogenicity of Mycoplasma pneumoniae in vasculitic/thrombotic disorders 

Much has been made of the recent, worldwide surge in cases of M. Pneumoniae (MP). Media reports invariably state that “nothing is out of the ordinary,” “cycles of increased respiratory diseases are to be expected” as well as blaming “lockdowns” as explanations and causes. This is incredible. 

Let’s focus on the Spike Protein. If we look at the literature, it has been suggested that mRNA vaccination with the Spike Protein has caused reactivation of viruses such as Epstein-Barr and Herpesviruses. 

Recently, case reports of COVID-19 vaccination-related hemophagocytic lymphohistiocytosis have been published. Although the mechanisms and risk factors for EBV-LPD after BNT162b2 mRNA COVID-19 vaccination remain unknown, it is important to note the possibility of reactivation of EBV after COVID-19 vaccination to initiate early and targeted therapy. 

[Epstein-Barr virus-associated lymphoproliferative disorders after BNT162b2 mRNA COVID-19 vaccination] 
https://pubmed.ncbi.nlm.nih.gov/37121772/ 

In conclusion, our study showed the possible association between COVID-19 vaccination and herpesvirus reactivation. The evidence for VZV and HSV was supported by observational studies. However, regarding other herpesviruses (EBV and CMV), further research especially from observational studies and clinical trials is required to elucidate the interaction between COVID-19 vaccination and their reactivation. 

Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413536/ 

What most people do not realize is that MP takes quite some time to develop. It is not something you catch and a few days later you have symptomatic MP. It takes weeks to cause symptoms. Also, only 5%-10% of those infected develop pneumonia. And, as we will discover in a quote below, finding pathogenic mycoplasmas in asymptomatic subjects is quite routine. 

It has an incubation period that ranges between 2 to 3 weeks. Like most respiratory pathogens, infection usually occurs during the winter months but can happen year-round. Estimates show that around 1% of the population of the United States is infected annually. Incidence may be much higher since infection can be subclinical or cause milder disease that does not require hospitalization. Outbreaks of mycoplasma infection occur in military recruits, hospitals, nursing homes, and other long-term care facilities. Only 5 to 10% of people infected with Mycoplasma develop pneumonia. It causes upper and lower respiratory tract infections in all age groups, particularly more than 5 years and less than 40 years of age. 

Mycoplasma Pneumonia 
https://www.ncbi.nlm.nih.gov/books/NBK430780/ 

The point I am making with this post, is that MP has the ability, like Epstein-Barr and Herpesviruses, to be a persistent infection. 

M. pneumoniae was present in the lower airways of chronic, stable asthmatics with greater frequency than control subjects, and may play a role in the pathogenesis of chronic asthma. 

Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma 
https://pubmed.ncbi.nlm.nih.gov/9731038/ 

Mycoplasma pneumoniae and Chlamydia pneumoniae, are probably able to cause persistent infections and might be involved in the pathogenesis of asthma. 

Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae 
https://erj.ersjournals.com/content/19/3/546 

And MP is also considered to be implicated in many chronic diseases.  

Pathogenic mycoplasmal infections have been found in a variety of human diseases and conditions. First, pathogenic mycoplasmas have been detected at higher incidence in blood and tissue specimens obtained from patients with various chronic illnesses compared to comparable healthy controls. Since the possible involvement of mycoplasmas in the cause and pathogenesis of chronic illnesses have not been firmly established, it remains uncertain whether such mycoplasmas are causal agents, cofactors, or opportunistic infections or co-infections in patients with various diagnoses. As stated above, various mycoplasmas can be found as normal flora in the genitourinary tract, oral cavity, gut and other sites, but they are not thought to be pathogenic at these superficial sites. 

The determining factor on whether mycoplasma infections are pathogenic in various diseases and illnesses or simply bystanders could be the requirement that pathogenic mycoplasmas must penetrate into the blood circulation and eventually enter into tissues and cells. This could explain the routine result of finding pathogenic mycoplasmas in the genitourinary tract, oral cavity, gut and occasionally in the blood of asymptomatic subjects. Unless mycoplasmas penetrate into the blood circulation and eventually enter tissues and cells, it may be unlikely that they can exert their full pathogenic effects. 

Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments 
https://www.scirp.org/journal/paperinformation.aspx?paperid=95720 

Interestingly, like Epstein-Barr and Herpesviruses, MP is simply something that many simply “have.” I am researching the mechanisms which allow for the exacerbation/reactivation of these pathogens by the Spike Protein.  

Thank you for your readership and support.